Tag:
MGI Pharma
Latest Headlines
Latest Headlines
Tesaro lands $101M B round as it preps for new cancer drug acquisitions
The veteran crew of cancer drug developers at MGI Pharma who went on to found Tesaro a little more than a year ago have rounded up a whopping $101 million B round led by Kleiner Perkins Caufield
MGI alum garner $60M to launch new cancer drug developer
A group of MGI Pharma alumni is launching a Boston-based startup named Tesaro in Boston with $60 million in venture backing for its plan to acquire, develop and commercialize new cancer drugs. The
Eisai inks $255M deal to buy AkaRx
New Jersey-based AkaRx is getting bought out for $255 million by Japan's Eisai, which picked up the option to buy the developer when it scooped up MGI Pharma in a $3.9 billion buyout almost two years
Eisai sedative not approvable
A sedative Eisai gained through its acquisition of MGI Pharma has been hit with a ‘not approvable' letter from the FDA. But the pharma company says it strongly believes that further talks with
Eisai wins expert panel's approval for new sedative
Backed by a positive review from FDA staffers, an expert panel at the agency has recommended the agency approve Eisai's fospropofol disodium, a sedative designed for use in a number of procedures,
FDA staffers say that Eisai sedative appears safe
FDA staffers say that an experimental sedative developed by Eisai appears to be safe, but wants outside experts to consider whether it's safe enough to be administered by workers untrained in
Eisai expands U.S. ops with $3.9B MGI buyout
A little over a week after announcing that it would explore its " strategic alternatives ," MGI Pharma
Lehman helps MGI study its 'strategic alternatives'
The speculation swirling around MGI Pharma is heating up with this morning's terse announcement that it has brought in Lehman Brothers to help the board evaluate its "strategic alternatives." Let's
DEALS: Solvay, Merck Serono ink deals with Gene Logic
Solvay, Merck Serono ink deals with Gene Logic DEALSWHOWITHWHATSCOOPInvusLexicon Pharmaceuticals$550 investmentLexicon will use the money to finance its 10 to 10 program, which
MGI lands $255M buyout option in drug deal
MGI Pharma has shelled out $45 million as a down payment for a Phase II therapy for thrombocytopenia, an abnormal drop in blood cells involved in forming blood clots. MGI says the deal to
